Multiple Factors Contribute to Disparities in Health and Cancer Outcomes
The issue of disparities in cancer is multifactorial, as it can cover not only race, ethnic, and cultural issues, but also gender identification.
Testing, Treatment Options Added to NCCN CRC Guidelines
A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.
PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy
PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.
Germline Testing Emphasized in NCCN Guidelines on Pancreatic Cancer
In recent years, pancreatic has passed breast cancer as the third leading cause of cancer death in the United States, and by 2030 it could be the leading cause.
New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground
New prostate cancer screening guidelines that seek to balance overtreatment concerns with the need to preserve gains in curbing prostate cancer mortality were unveiled at the National Comprehensive Cancer Network's 19th Annual Conference.
T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression
Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer
Dr Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer
2 Clarke Drive Cranbury, NJ 08512